About
Technology
Issues
FAQ
Links
Official Page
1020O A phase I, first-in-human, open-label, dose escalation study of MGD019, an investigational bispecific PD-1 x CTLA-4 DART® molecule in patients with advanced solid tumours
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.